Research programme: multiple myeloma therapeutics - MannKind Corporation

Drug Profile

Research programme: multiple myeloma therapeutics - MannKind Corporation

Alternative Names: Inositol requiring enzyme-1 inhibitor; IRE-1α inhibitor; MKC 204; MKC-3946

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator MannKind Corporation
  • Class Small molecules
  • Mechanism of Action ERN1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-myeloma in USA
  • 31 May 2012 Pharmacodynamics data from preclinical studies in Multiple myeloma released by MannKind
  • 16 Mar 2010 Preclinical trials in Multiple myeloma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top